Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. 2009

Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, People's Republic of China.

Fatty acid biosynthesis is essential for bacterial survival. Components of this biosynthetic pathway have been identified as attractive targets for the development of new antibacterial agents. FabH, beta-ketoacyl-acyl carrier protein (ACP) synthase III, is a particularly attractive target, since it is central to the initiation of fatty acid biosynthesis and is highly conserved among Gram positive and negative bacteria. Three series of Schiff bases containing thiazole template were synthesized and developed as potent inhibitors of FabH. This inhibitor class demonstrates strong antibacterial activity. Escherichia coli FabH inhibitory assay and docking simulation indicated that the compounds 11 and 18 were potent inhibitors of E. coli FabH.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D015099 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase An enzyme of long-chain fatty acid synthesis, that adds a two-carbon unit from malonyl-(acyl carrier protein) to another molecule of fatty acyl-(acyl carrier protein), giving a beta-ketoacyl-(acyl carrier protein) with the release of carbon dioxide. EC 2.3.1.41. 3 Oxoacyl (Acyl Carrier Protein) Synthase,3-Keto-ACP Synthase,3-Oxoacyl (Acyl Carrier Protein) Synthase,3-Oxoacyl Synthetase,Acyl-Malonyl-ACP Condensing Enzyme,beta Keto Acyl Synthetase,beta Keto-Acyl Carrier Protein Synthase I,beta Keto-Acyl Carrier Protein Synthase II,beta Ketoacyl ACP Synthase,beta-Ketoacyl-Coenzyme A (CoA) Synthase,3 Keto ACP Synthase,3 Oxoacyl Synthetase,Acyl Malonyl ACP Condensing Enzyme,Condensing Enzyme, Acyl-Malonyl-ACP,Synthase, 3-Keto-ACP,Synthetase, 3-Oxoacyl,beta Keto Acyl Carrier Protein Synthase I,beta Keto Acyl Carrier Protein Synthase II
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
March 2014, European journal of medicinal chemistry,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
May 2024, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
January 2017, Chemical biology & drug design,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
January 2021, Bioorganic & medicinal chemistry,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
April 2016, Bioorganic chemistry,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
June 2013, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
February 2017, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
September 2014, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
November 2014, Bioorganic & medicinal chemistry letters,
Peng-Cheng Lv, and Kai-Rui Wang, and Ying Yang, and Wen-Jun Mao, and Jin Chen, and Jing Xiong, and Hai-Liang Zhu
December 2018, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!